Taysha Gene Therapies Files 2023 Annual Report on Form 10-K

Ticker: TSHA · Form: 10-K · Filed: Mar 19, 2024 · CIK: 1806310

Sentiment: neutral

Topics: 10-K, Taysha Gene Therapies, Gene Therapy, Clinical Trials, Biotechnology

TL;DR

<b>Taysha Gene Therapies, Inc. has filed its 2023 10-K report, outlining its business operations, agreements, and financial activities for the fiscal year ending December 31, 2023.</b>

AI Summary

Taysha Gene Therapies, Inc. (TSHA) filed a Annual Report (10-K) with the SEC on March 19, 2024. Taysha Gene Therapies, Inc. filed its 2023 Form 10-K on March 19, 2024, reporting on its fiscal year ending December 31, 2023. The filing details various agreements and activities, including the acquisition of worldwide rights for TSHA-120 for Giant Axonal Neuropathy from Astellas in March 2021. Key dates mentioned include the Astellas agreement in October 2022 and a securities purchase agreement involving private placement and pre-funded warrants on August 14, 2023. The company's business address is 3000 Pegasus Park Drive, Suite 1430, Dallas, TX 75247. The filing covers the period from January 1, 2023, to December 31, 2023, and references prior periods for financial and operational context.

Why It Matters

For investors and stakeholders tracking Taysha Gene Therapies, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Taysha Gene Therapies' business, including its gene therapy development pipeline and strategic partnerships, which are crucial for investors to assess the company's progress and future prospects. The detailed information on agreements, such as those with Astellas and the securities purchase agreement, offers insights into the company's financing and collaboration strategies, impacting its ability to fund research and development and bring therapies to market.

Risk Assessment

Risk Level: — Taysha Gene Therapies, Inc. shows moderate risk based on this filing. The company operates in the highly regulated and competitive biotechnology sector, with significant R&D costs and clinical trial risks, as evidenced by the numerous agreements and the focus on gene therapy development for rare diseases.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand the company's cash burn rate, funding needs, and the progress of its clinical programs.

Key Numbers

Key Players & Entities

FAQ

When did Taysha Gene Therapies, Inc. file this 10-K?

Taysha Gene Therapies, Inc. filed this Annual Report (10-K) with the SEC on March 19, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Taysha Gene Therapies, Inc. (TSHA).

Where can I read the original 10-K filing from Taysha Gene Therapies, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Taysha Gene Therapies, Inc..

What are the key takeaways from Taysha Gene Therapies, Inc.'s 10-K?

Taysha Gene Therapies, Inc. filed this 10-K on March 19, 2024. Key takeaways: Taysha Gene Therapies, Inc. filed its 2023 Form 10-K on March 19, 2024, reporting on its fiscal year ending December 31, 2023.. The filing details various agreements and activities, including the acquisition of worldwide rights for TSHA-120 for Giant Axonal Neuropathy from Astellas in March 2021.. Key dates mentioned include the Astellas agreement in October 2022 and a securities purchase agreement involving private placement and pre-funded warrants on August 14, 2023..

Is Taysha Gene Therapies, Inc. a risky investment based on this filing?

Based on this 10-K, Taysha Gene Therapies, Inc. presents a moderate-risk profile. The company operates in the highly regulated and competitive biotechnology sector, with significant R&D costs and clinical trial risks, as evidenced by the numerous agreements and the focus on gene therapy development for rare diseases.

What should investors do after reading Taysha Gene Therapies, Inc.'s 10-K?

Investors should review the detailed financial statements and risk factors in the 10-K to understand the company's cash burn rate, funding needs, and the progress of its clinical programs. The overall sentiment from this filing is neutral.

Risk Factors

Key Dates

Filing Stats: 4,484 words · 18 min read · ~15 pages · Grade level 15 · Accepted 2024-03-19 16:15:31

Key Financial Figures

Filing Documents

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 32 Item 1B. Unresolved Staff Comments 84 Item 1C. Cybersecurity 84 Item 2.

Properties

Properties 85 Item 3.

Legal Proceedings

Legal Proceedings 85 Item 4. Mine Safety Disclosures 85 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 86 Item 6. Reserved 86 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operation

Management's Discussion and Analysis of Financial Condition and Results of Operation 87 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 100 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data F- 1 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 101 Item 9A.

Controls and Procedures

Controls and Procedures 101 Item 9B. Other Information 101 Item 9C. Disclosure Regarding Foreign Jurisdiction that Prevent Inspections 101 PART III Item 10. Directors, Executive Officers and Corporate Governance 102 Item 11.

Executive Compensation

Executive Compensation 102 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 102 Item 13. Certain Relationships and Related Transactions, and Director Independence 102 Item 14. Principal Accounting Fees and Services 102 PART IV Item 15. Exhibits and Financial Statement Schedules 103 Item 16. Form 10-K Summary 105

Signatures

Signatures 106 i SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K, or this Annual Report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part I, Item 1. "Business," Part I, Item 1A. "Risk Factors," and Part II, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations," but are also contained elsewhere in this Annual Report. In some cases, you can identify forward-looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward-looking statements include statements about: the timing, progress and results of our preclinical studies and clinical trials of our product candidates, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research

Bu siness

Item 1. Bu siness. Overview We are a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. Our lead clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, we aim to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. Our management team has proven experience in gene therapy development and commercialization. We leverage this experience, our manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. In March 2022, we announced strategic pipeline prioritization initiatives focused on giant axonal neuropathy, or GAN, and Rett syndrome, and we have subsequently further paused substantially all other research and development activities to increase operational efficiency. Further, in September 2023, we announced that subsequent to the receipt of Type C meeting feedback from the United States Food and Drug Administration, or FDA, regarding a registrational path for TSHA-120, we were discontinuing the development of our TSHA-120 program in evaluation for the treatment of GAN. We initiated the transfer of the FDA Investigational New Drug, or IND, application and investigational clinical trial material for TSHA-120 in GAN to clinical trial collaborator National Institute of Neurological Disorders and Stroke (NINDS), creating an opportunity for continued clinical evaluation of TSHA-120 in GAN. Additionally, we initiated discussions with the originating advocacy organization regarding TSHA-120 in an effort to transfer rights back to the advocacy organization to move the program forward. We are evaluating TSHA-1

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing